Vodafone and AstraZeneca disappoint in tough times

ReutersNewsPublished: February 2, 20172 views
Published: February 2, 2017

Two of Britain's biggest global players have reported disappointing results. AstraZeneca has warned profit and revenue will fall this year as cheap generic versions of its cholesterol drug Crestor continue to hit sales and cut-throat competition in India and an onslaught from rivals in its home market prompted Vodafone to nudge its full-year earnings guidance down. Sonia Legg reports.

Be the first to suggest a tag